FEATURED EDITORIAL
With House passage of the FDA Modernization Act 3.0, Congress has taken another major step toward modernizing biomedical research and drug development.
- Pharmacogenomics In Oncology: A Pharmacokinetic Perspective
- From Valency To Vaccine Design: The Changing Competitive Landscape In Pneumococcal Vaccines
- Rhogam's Unconventional History And Why There Is No True Synthetic Replacement (Part 2 of 3)
- Can We Cure Diabetes?
- Botanical Therapeutics For CNS Disorders
- Wondering If Your Org Should Purchase R&D Datasets?
- iBio Aims To Complement GLP-1s By Preserving Muscle During Weight Loss With Myostatin Antibody
FEATURED APPLICATION CONTENT
-
Personalized medicine struggles with models that fail to reflect real human biology. Organ-on-a-Chip systems recreate tissue complexity, helping predict patient-specific treatment responses.
-
Modeling the human brain requires more than simplified systems. New approaches that incorporate diverse cell types are improving how researchers study neurovascular function with greater precision.
-
Centralizing data unlocks faster insights, reduces duplicated effort, and improves compliance. By overcoming silos and “dark data,” organizations can enable efficient search, reuse, and analysis.
-
See how existing partnerships with NIH allowed the chance to bring together government, academic, and industry resources through strategic initiatives that streamline processes and maximize benefits.
-
See how a biotechnology company advanced an engineered protein therapeutic while navigating development, regulatory, and scalability challenges.
-
Integrated accelerated stability workflows reduce manual data handling while improving confidence in shelf‑life predictions. Help your teams move faster with fewer experimental demands.
-
Confident identification of known and unknown compounds starts with smarter LC/MS and GC/MS workflows. Learn how structure elucidation, verification, and centralized data curation work together.
-
Gain insight into how localized modeling of ionizable centers, supported by curated experimental data, delivers reliable predictions that strengthen physicochemical decision-making.
-
Property-driven optimization helps medicinal chemists focus synthetic effort where it matters most. See how integrating ADME and physicochemical predictions can surface better-balanced lead candidates.
-
Digital integration of physicochemical property prediction transforms how chemists evaluate compounds, enabling faster analysis, stronger structure, and more informed decisions across libraries.
-
Automated structure verification integrated into open-access NMR workflows cuts review time dramatically while maintaining confidence in results. See how smart parameter optimization improves efficiency.
-
High-throughput chemistry delivers speed and efficiency, but only with the right digital backbone. See how integrated automation and analytics help chemists extract more value from every plate.
- Rhogam's Unconventional History And Why There Is No True Synthetic Replacement (Part 2 of 3)
- iBio Aims To Complement GLP-1s By Preserving Muscle During Weight Loss With Myostatin Antibody
- How Rh Incompatibility Endangers Pregnancies And How Rhogam Helped My Family (Part 1 of 3)
- 2026 Nucleate Boston Activator Cohort Interview: Arvin Soepriatna — TEEM Therapeutics
- 2026 Nucleate Boston Activator Cohort Interview: Ryan Posey & Anusha Manglik — Resilientia Therapeutics
DRUG DISCOVERY CONTENT COLLECTIONS
Drug discovery is moving beyond traditional hit identification toward data-driven strategies that extract deeper insight from large-scale screening datasets. Advances in DNA-encoded library (DEL) screening, computational tools, and machine learning are helping teams make more informed decisions in early-stage drug development. Access this brand-new Drug Discovery Online content collection for an under-the-hood look at modern approaches to turning large discovery datasets into actionable insight.
FEATURED NEWS HEADLINES
- SITC Announces EU Immuno-Oncology Drug Development Summit - Bringing The European IO Community Together To Foster The Next Wave Of IO Therapeutics
- Lonza And Engitix Announce License Agreement To Advance Targeted ADC Development
- Tract Bio Announces Presentations At Two AACR Conferences
- Acrivon To Highlight The Power Of Its AP3 Platform For Streamlined, Pathway-Based Drug Discovery And Development With Oral And Poster Presentations At AACR D3 Conference
- Phanes Therapeutics Announces Expansion Of Clinical Trial Collaboration And Supply Agreement With Merck To Evaluate Spevatamig In Combination With KEYTRUDA® (Pembrolizumab) And Chemotherapy For Treatment Of Biliary Tract Cancer
- TriLink BioTechnologies Further Strengthens Global IP Position With Newly Issued Patent In China For CleanCap Capping Technology
- Biohaven To Present New Clinical Data At ESMO Congress On BHV-1530, A Novel FGFR3-Directed ADC With A Proprietary Topoisomerase I (TopoIx) Payload
- Consano Bio Receives FDA Investigational New Drug Clearance To Expand The C-1101 Chronic Sciatica Clinical Development Program Into The United States
- Illumina Expands Billion Cell Atlas Program With New AI Drug Developers
- Crown Bioscience Joins C-Path's NAMs Developer Coalition To Advance Human-Relevant Models In Drug Development
ARCHIVED NEWSLETTER
- 07.22.26 -- Advancing Spatial Multiomics For Discovery: From Promise To Practice
- 07.21.26 -- Advancing Spatial Multiomics For Discovery: From Promise To Practice
- 07.15.26 -- Human-Centric Models For Modern Drug Development
- 07.14.26 -- iBio Aims To Complement GLP-1s By Preserving Muscle During Weight Loss With Myostatin Antibody
- 07.07.26 -- Discovery Dialogues: Winston Haynes, VP, Computational Sciences And Engineering, LabGenius Tx
